A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumours

Trial Profile

A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Azacitidine (Primary) ; Carboplatin; Paclitaxel
  • Indications Anal cancer; Bladder cancer; Cervical cancer; Fallopian tube cancer; Merkel cell carcinoma; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record
    • 25 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top